Cover Image
市場調查報告書

胰臟癌:開發中產品分析

Pancreatic Cancer - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 200987
出版日期 內容資訊 英文 1827 Pages
訂單完成後即時交付
價格
Back to Top
胰臟癌:開發中產品分析 Pancreatic Cancer - Pipeline Review, H1 2016
出版日期: 2016年06月28日 內容資訊: 英文 1827 Pages
簡介

所謂胰臟癌 ,是胰臟組織產生惡性細胞(癌症細胞)這樣的疾病,又稱外分泌系統癌症。主要的前兆、症狀,是腹上部痛與擴散到背部、黃疸、食慾不振、體重減少、憂鬱症、血塊等。在主要的易罹病素質上有年齡和性別、抽煙、糖尿病、家族病史等。主要的治療方法中,包含外科手術、化療、放射治療等。

本報告提供全球各國的胰臟癌治療用的開發中產品的開發情形相關分析著開發中產品的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查。

簡介

胰臟癌概要

治療藥的開發

胰臟癌:企業開發中的治療藥

胰臟癌:大學/機關研究中的治療藥

胰臟癌:開發中產品概況

胰臟癌:企業開發中的產品

胰臟癌:大學/機關研究中的產品

胰臟癌的治療藥開發企業

胰臟癌:治療藥的評估

藥物簡介

胰臟癌:暫停中的計劃

胰臟癌:開發中止的產品

胰臟癌:產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7953IDB

Summary

Global Markets Direct's, 'Pancreatic Cancer - Pipeline Review, H1 2016', provides an overview of the Pancreatic Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pancreatic Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pancreatic Cancer
  • The report reviews pipeline therapeutics for Pancreatic Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Pancreatic Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Pancreatic Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Pancreatic Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Pancreatic Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Pancreatic Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Pancreatic Cancer Overview
  • Therapeutics Development
  • Pancreatic Cancer - Therapeutics under Development by Companies
  • Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes
  • Pancreatic Cancer - Pipeline Products Glance
  • Pancreatic Cancer - Products under Development by Companies
  • Pancreatic Cancer - Products under Investigation by Universities/Institutes
  • Pancreatic Cancer - Companies Involved in Therapeutics Development
  • Pancreatic Cancer - Therapeutics Assessment
  • Drug Profiles
  • Pancreatic Cancer - Dormant Projects
  • Pancreatic Cancer - Discontinued Products
  • Pancreatic Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Pancreatic Cancer, H1 2016
  • Number of Products under Development for Pancreatic Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Development by Companies, H1 2016 (Contd..9)
  • Number of Products under Development by Companies, H1 2016 (Contd..10)
  • Number of Products under Development by Companies, H1 2016 (Contd..11)
  • Number of Products under Development by Companies, H1 2016 (Contd..12)
  • Number of Products under Development by Companies, H1 2016 (Contd..13)
  • Number of Products under Development by Companies, H1 2016 (Contd..14)
  • Number of Products under Development by Companies, H1 2016 (Contd..15)
  • Number of Products under Development by Companies, H1 2016 (Contd..16)
  • Number of Products under Development by Companies, H1 2016 (Contd..17)
  • Number of Products under Development by Companies, H1 2016 (Contd..18)
  • Number of Products under Development by Companies, H1 2016 (Contd..19)
  • Number of Products under Development by Companies, H1 2016 (Contd..20)
  • Number of Products under Development by Companies, H1 2016 (Contd..21)
  • Number of Products under Development by Companies, H1 2016 (Contd..22)
  • Number of Products under Development by Companies, H1 2016 (Contd..23)
  • Number of Products under Development by Companies, H1 2016 (Contd..24)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Development by Companies, H1 2016 (Contd..13)
  • Products under Development by Companies, H1 2016 (Contd..14)
  • Products under Development by Companies, H1 2016 (Contd..15)
  • Products under Development by Companies, H1 2016 (Contd..16)
  • Products under Development by Companies, H1 2016 (Contd..17)
  • Products under Development by Companies, H1 2016 (Contd..18)
  • Products under Development by Companies, H1 2016 (Contd..19)
  • Products under Development by Companies, H1 2016 (Contd..20)
  • Products under Development by Companies, H1 2016 (Contd..21)
  • Products under Development by Companies, H1 2016 (Contd..22)
  • Products under Development by Companies, H1 2016 (Contd..23)
  • Products under Development by Companies, H1 2016 (Contd..24)
  • Products under Development by Companies, H1 2016 (Contd..25)
  • Products under Development by Companies, H1 2016 (Contd..26)
  • Products under Development by Companies, H1 2016 (Contd..27)
  • Products under Development by Companies, H1 2016 (Contd..28)
  • Products under Development by Companies, H1 2016 (Contd..29)
  • Products under Development by Companies, H1 2016 (Contd..30)
  • Products under Development by Companies, H1 2016 (Contd..31)
  • Products under Development by Companies, H1 2016 (Contd..32)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..3)
  • Pancreatic Cancer - Pipeline by 3-V Biosciences, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by 4SC AG, H1 2016
  • Pancreatic Cancer - Pipeline by AB Science SA, H1 2016
  • Pancreatic Cancer - Pipeline by AbbVie Inc., H1 2016
  • Pancreatic Cancer - Pipeline by AbGenomics International, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Ability Pharmaceuticals, S.L., H1 2016
  • Pancreatic Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by ACF Pharmaceuticals, LLC, H1 2016
  • Pancreatic Cancer - Pipeline by Adamed Sp. z o.o., H1 2016
  • Pancreatic Cancer - Pipeline by Adamis Pharmaceuticals Corporation, H1 2016
  • Pancreatic Cancer - Pipeline by Aduro BioTech, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Advantagene, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Advaxis, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Agenus, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by AGV Discovery, SAS, H1 2016
  • Pancreatic Cancer - Pipeline by AIMM Therapeutics B.V., H1 2016
  • Pancreatic Cancer - Pipeline by Alchemia Limited, H1 2016
  • Pancreatic Cancer - Pipeline by Alethia Biotherapeutics Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Allinky Biopharma, H1 2016
  • Pancreatic Cancer - Pipeline by Almac Discovery Limited, H1 2016
  • Pancreatic Cancer - Pipeline by Altor BioScience Corporation, H1 2016
  • Pancreatic Cancer - Pipeline by Ambrx, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by American Gene Technologies International Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Amgen Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Anavex Life Sciences Corp., H1 2016
  • Pancreatic Cancer - Pipeline by Andarix Pharmaceuticals, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by ANP Technologies, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by AntiCancer, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by APEIRON Biologics AG, H1 2016
  • Pancreatic Cancer - Pipeline by Aphios Corporation, H1 2016
  • Pancreatic Cancer - Pipeline by APIM Therapeutics AS, H1 2016
  • Pancreatic Cancer - Pipeline by Apogenix GmbH, H1 2016
  • Pancreatic Cancer - Pipeline by Aposense Ltd., H1 2016
  • Pancreatic Cancer - Pipeline by ArQule, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Array BioPharma Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Astellas Pharma Inc., H1 2016
  • Pancreatic Cancer - Pipeline by AstraZeneca Plc, H1 2016
  • Pancreatic Cancer - Pipeline by ATLAB Pharma SAS, H1 2016
  • Pancreatic Cancer - Pipeline by Aurigene Discovery Technologies Limited, H1 2016
  • Pancreatic Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Axcentua Pharmaceuticals AB, H1 2016
  • Pancreatic Cancer - Pipeline by Azaya Therapeutics, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Basilea Pharmaceutica AG, H1 2016
  • Pancreatic Cancer - Pipeline by Bavarian Nordic A/S, H1 2016
  • Pancreatic Cancer - Pipeline by Bayer AG, H1 2016
  • Pancreatic Cancer - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Berg LLC, H1 2016
  • Pancreatic Cancer - Pipeline by BerGenBio AS, H1 2016
  • Pancreatic Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H1 2016
  • Pancreatic Cancer - Pipeline by Bexion Pharmaceuticals, LLC., H1 2016
  • Pancreatic Cancer - Pipeline by Biomar Microbial Technologies, H1 2016
  • Pancreatic Cancer - Pipeline by Biomunex Pharmaceuticals, H1 2016
  • Pancreatic Cancer - Pipeline by Bioncotech Therapeutics S.L., H1 2016
  • Pancreatic Cancer - Pipeline by Bionomics Limited, H1 2016
  • Pancreatic Cancer - Pipeline by BioNTech AG, H1 2016
  • Pancreatic Cancer - Pipeline by BiOrion Technologies B.V., H1 2016
  • Pancreatic Cancer - Pipeline by Biotest AG, H1 2016
  • Pancreatic Cancer - Pipeline by Biouniversa s.r.l., H1 2016
  • Pancreatic Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Pancreatic Cancer - Pipeline by Boston Biomedical, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Pancreatic Cancer - Pipeline by Cadila Pharmaceuticals Limited, H1 2016
  • Pancreatic Cancer - Pipeline by Calithera Biosciences, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Cantargia AB, H1 2016
  • Pancreatic Cancer - Pipeline by Cascadian Therapeutics Inc, H1 2016
  • Pancreatic Cancer - Pipeline by Cavion LLC, H1 2016
  • Pancreatic Cancer - Pipeline by Celgene Corporation, H1 2016
  • Pancreatic Cancer - Pipeline by Cellceutix Corporation, H1 2016
  • Pancreatic Cancer - Pipeline by Cellectis S.A., H1 2016
  • Pancreatic Cancer - Pipeline by Cellular Biomedicine Group, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Celprogen, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Celsion Corporation, H1 2016
  • Pancreatic Cancer - Pipeline by Centrose LLC, H1 2016
  • Pancreatic Cancer - Pipeline by Ceronco Biosciences, H1 2016
  • Pancreatic Cancer - Pipeline by ChemoCentryx, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Chiome Bioscience, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Clovis Oncology, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Coare Biotechnology, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Concordia Healthcare Corp., H1 2016
  • Pancreatic Cancer - Pipeline by Confluence Life Sciences, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016
  • Pancreatic Cancer - Pipeline by CritiTech, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by CrystalGenomics, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by CTI BioPharma Corp., H1 2016
  • Pancreatic Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by CytomX Therapeutics, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by CytRx Corporation, H1 2016
  • Pancreatic Cancer - Pipeline by CyTuVax B.V., H1 2016
  • Pancreatic Cancer - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016
  • Pancreatic Cancer - Pipeline by DEKK-TEC, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Diffusion Pharmaceuticals Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Eisai Co., Ltd., H1 2016
  • Pancreatic Cancer - Pipeline by Eleison Pharmaceuticals LLC, H1 2016
  • Pancreatic Cancer - Pipeline by Eli Lilly and Company, H1 2016
  • Pancreatic Cancer - Pipeline by Endor Nanotechnologies SL, H1 2016
  • Pancreatic Cancer - Pipeline by Ensol Biosciences Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Erytech Pharma SA, H1 2016
  • Pancreatic Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Etubics Corporation, H1 2016
  • Pancreatic Cancer - Pipeline by Exelixis, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Pancreatic Cancer - Pipeline by FibroGen, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Five Prime Therapeutics, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Forty Seven Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Fountain Biopharma Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Fujifilm Corporation, H1 2016
  • Pancreatic Cancer - Pipeline by Fusion Antibodies Limited, H1 2016
  • Pancreatic Cancer - Pipeline by GamaMabs Pharma S.A., H1 2016
  • Pancreatic Cancer - Pipeline by Ganymed Pharmaceuticals AG, H1 2016
  • Pancreatic Cancer - Pipeline by Geistlich Pharma AG, H1 2016
  • Pancreatic Cancer - Pipeline by Genelux Corporation, H1 2016
  • Pancreatic Cancer - Pipeline by Genentech, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Genisphere Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Genmab A/S, H1 2016
  • Pancreatic Cancer - Pipeline by Gilead Sciences, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Pancreatic Cancer - Pipeline by Globeimmune, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by GlycoMimetics, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Golden Biotechnology Corp., H1 2016
  • Pancreatic Cancer - Pipeline by GW Pharmaceuticals Plc, H1 2016
  • Pancreatic Cancer - Pipeline by Halozyme Therapeutics, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by HEC Pharm Co., Ltd., H1 2016
  • Pancreatic Cancer - Pipeline by Helix BioPharma Corp., H1 2016
  • Pancreatic Cancer - Pipeline by iCeutica, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Ignyta, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Immodulon Therapeutics Ltd., H1 2016
  • Pancreatic Cancer - Pipeline by Immune Pharmaceuticals Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Immune System Key Ltd., H1 2016
  • Pancreatic Cancer - Pipeline by Immunomedics, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Immunotope, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Immunovo BV, H1 2016
  • Pancreatic Cancer - Pipeline by Immupharma Plc, H1 2016
  • Pancreatic Cancer - Pipeline by Incuron, LLC, H1 2016
  • Pancreatic Cancer - Pipeline by Incyte Corporation, H1 2016
  • Pancreatic Cancer - Pipeline by Inflection Biosciences Limited, H1 2016
  • Pancreatic Cancer - Pipeline by Innopharmax Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Intica Biomedical, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Inventiva, H1 2016
  • Pancreatic Cancer - Pipeline by Io Therapeutics, Inc., H1 2016
  • Pancreatic Cancer - Pipeline by Ipsen S.A., H1 2016
  • Pancreatic Cancer - Pipeline by Jasco Pharmaceuticals, LLC., H1 2016
  • Pancreatic Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016
  • Pancreatic Cancer - Pipeline by Johnson & Johnson, H1 2016

List of Figures

  • Number of Products under Development for Pancreatic Cancer, H1 2016
  • Number of Products under Development for Pancreatic Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top